Last updated 17 days ago

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

2150 patients around the world

Available in Puerto Rico, Chile, Argentina, United States, Spain, Brazil, Mexico

Akero Therapeutics, Inc

2150Patients around the world

This study is for people with

Fatty liver/nash

Nonalcoholic steatohepatitis

Steatohepatitis

Metabolic dysfunction-associated steatohepatitis - MASH

Cirrhosis

Compensated cirrhosis

To 80 Years

All Gender

: Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH.
Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH.

: Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.
Type 1 diabetes or unstable Type 2 diabetes.
Any current or prior history of decompensated liver disease.

SponsorAkero Therapeutics, Inc

Study typeInterventional

Conditions

Nonalcoholic steatohepatitisMetabolic dysfunction-associated steatohepatitis - MASHCompensated cirrhosis

Requirements

To 80 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06528314